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Abstract
Objectives Conventional and quantitative MRI was per-
formed in patients with chronic progressive external
ophthalmoplegia (CPEO), a common manifestation of mito-
chondrial disease, to characterise MRI findings in the extra-
ocular muscles (EOMs) and investigate whether quantitative
MRI provides clinically relevant measures of disease.
Methods Patients with CPEO due to single mitochondrial
DNA deletions were compared with controls. Range of eye
movement (ROEM) measurements, peri-orbital 3 T MRI T1-
weighted (T1w) and short-tau-inversion-recovery (STIR) im-
ages, and T2 relaxation time maps were obtained. Blinded
observers graded muscle atrophy and T1w/STIR
hyperintensity. Cross-sectional areas and EOM mean T2s
were recorded and correlated with clinical parameters.
Results Nine patients and nine healthy controls were exam-
ined. Patients had reduced ROEM (patients 13.3°, controls
49.3°, p<0.001), greater mean atrophy score and increased
T1w hyperintensities. EOM mean cross-sectional area was
43 % of controls and mean T2s were prolonged (patients
75.6±7.0 ms, controls 55.2±4.1 ms, p<0.001). ROEM corre-
lated negatively with EOM T2 (rho=−0.89, p<0.01), whilst
cross-sectional area failed to correlate with any clinical
measures.
Conclusions MRI demonstrates EOM atrophy, characteristic
signal changes and prolonged T2 in CPEO. Correlation be-
tween elevated EOM T2 and ROEM impairment represents a
potential measure of disease severity that warrants further
evaluation.
Key Points
• Chronic progressive external ophthalmoplegia is a common
clinical manifestation of mitochondrial disease.
• Existing extra-ocular muscle MRI data in CPEO reports
variable radiological findings.
• MRI confirmed EOM atrophy and characteristic signal
changes in CPEO.
• EOM T2 was significantly elevated in CPEO and correlated
negatively with ocular movements.
• EOM T2 represents a potential quantitative measure of dis-
ease severity in CPEO.
Keywords Magnetic resonance imaging .Mitochondrial
diseases . Mitochondrial DNA . Chronic progressive external
ophthalmoplegia . Kearns-Sayre syndrome
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Introduction
There are currently no effective treatments for mitochondrial
diseases [1, 2]. One major obstacle to clinical trials is a lack of
reliable, non-invasive, reproducible biomarkers against which
disease progression and treatment response can be measured.
Chronic progressive external ophthalmoplegia (CPEO), a
common clinical manifestation of mitochondrial disease, is
characterised by gradually progressive reduction in the range
of eye movements (ROEM). It is usually sporadic, as occurs
with single large-scale deletions of mitochondrial DNA
(mtDNA) which have a reported point prevalence for clinical-
ly affected adults of 1.17 in 100,000 people [3]. However, it
can also be inherited in a maternal or Mendelian pattern de-
pending on whether the causative genetic defect resides in the
mitochondrial or nuclear genome. Imaging studies have re-
ported extra-ocular muscle (EOM) atrophy, sometimes asso-
ciated with EOM signal change, as a feature of CPEO. How-
ever, investigations have been, for the most part, limited to
small, genetically undefined patient series with rather variable
radiological findings [4–7]. For instance, CPEO has been as-
sociated with normal or near normal volumes despite clinical-
ly severe ophthalmoplegia on orbital T1-weighted (T1w)MRI
[6], whilst small EOMs are also reported using the same im-
aging modality [4, 5]. Furthermore, EOM MRI signal abnor-
mality in patients with CPEO, in the absence of orbital or
EOM inflammation, has previously been proposed as a possi-
ble discriminator from other conditions which cause
ophthalmoparesis [6]. However, this finding has not been rep-
licated in independent patient cohorts with CPEO.
Our purpose was to clarify the radiological appearance of
the EOMs in comparison with matched healthy individuals
studied concurrently and, by correlation with clinical mea-
sures, investigate the feasibility and validity of quantitative
MRI indices as functionally relevant markers of mitochondrial
disease severity. We therefore conducted a peri-orbital MRI
study in a genetically homogenous CPEO patient group with
single deletions of mtDNA. We aimed to define in patients
with CPEO the qualitative appearance of EOM on T1w and
short-tau inversion recovery (STIR) MRI images, EOM spin-
spin relaxation times (T2s) and cross-sectional areas, in
comparison with controls, and to correlate MRI findings with
clinical measures including ROEM.
Materials and methods
Patient and healthy control recruitment criteria
Nine adult patients referred to the NHS Specialised Services-
funded Mitochondrial Diagnostic Centre in London for inves-
tigation of CPEO and found to harbour a single, sporadically
occurring, mtDNA deletion in skeletal muscle, and nine age-
and gender-matched healthy controls were recruited. The
mean age of the patients was 33 years (range: 19–52 years)
with a mean age at symptom onset of 16 years (range: 12–
32 years). Four patients with a clinical diagnosis of Kearns-
Sayre syndrome (KSS) had a mean age at onset of 12 years
(range: 6–17 years). The remaining patients with CPEO had a
mean age of onset of 20 years (range: 14–32 years). The mean
age of the controls was 33 years (range: 26–43 years).
Institutional Research Ethics Committee approval for the
study, and accordingly individual subjects’ consent, was
obtained.
Clinical assessment of ocular movements
EOM function was quantified in terms of ROEM by measur-
ing ocular excursions (ductions) for each eye on the
Goldmann perimeter using, as in a previous CPEO study
[8], the modified uniocular field of fixation technique [9]. This
isolates the action of each individual muscle by recording
excursions only along the axes corresponding to that muscle’s
primary field of action. These are plotted on standard
Goldmann charts with pre-printed testing axes. For the right
eye the axes are: 0° (lateral rectus, LR); 67° (superior rectus,
SR); 141° (inferior oblique, IO); 180° (medial rectus, MR);
216° (superior oblique, SO); and 293° (inferior rectus, IR).
The left eye uses a chart which is the mirror image of the right
eye chart. Testing was performed uniocularly with chin and
head fixation and excursions repeated to ensure measurement
consistency within 5°.
Magnetic resonance imaging protocol
Imaging was performed at 3 T (TIM Trio, Siemens, Erlangen,
Germany) with a 32-channel receiver head coil. Subjects were
examined supine and headfirst and asked to keep their eyes
closed for the duration of each scan. Coronal images were
acquired with a field of view (FOV) of 162×200 mm.
Turbo-spin echo (TSE) T1w images were acquired with time
to repetition (TR)/time to echo (TE)=575/7.6 ms, 20×2-mm
slices, slice gap 1 mm, matrix 312×384. STIR images were
acquired with TR/TE/time to inversion=6760/8/220 ms,
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matrix 312×384 and 20×2-mm slices, slice gap 1 mm. T2
was measured with a multiple spin-echo sequence (TR=
4060 ms, 22 spin-echoes with TEs 8.6–189.2 ms and an echo
spacing of 8.6 ms, matrix 208×256, 12×3-mm slices, 0.3-mm
gap, 180° refocusing pulses). Total imaging time was less than
20 min.
Qualitative magnetic resonance imaging evaluation
All MRI analysis was performed by observers blinded to the
subject clinical details, including patient versus control status.
The coronal T1w and STIR orbital images were systematical-
ly reviewed by two experienced neuroradiologists (I.D. and
T.Y.). The individual characteristics of all 12 EOMs were
reviewed sequentially in all subjects and the consensus opin-
ion was recorded. A scoring system was applied to capture the
following qualitative features: degree of atrophy (normal=0,
mild=1, marked=2); STIR hyperintensity (normal=0, hyper-
intense=1); and presence or absence of T1w hyperintensity
foci with anatomically coincident STIR hypointensity (pre-
sumed to represent fatty infiltration), taking account of the
intra-EOM pattern: the intrinsic foci were observed to either
be of approximately equal diameter in all dimensions in the
coronal plane, termed 'dots', or elongated in one dimension
(invariably in-line with the longest dimension of the extra-
ocular muscle in the coronal section), termed 'streaks’. Where
both dots and streaks were observed in different sections
through a single EOM, the convention adopted was to record
the muscle as demonstrating an intrinsic 'streak' signal. The
qualitative scores were tabulated for both healthy controls and
CPEO patients.
Measurement of cross-sectional area
Cross-sectional areas of the five EOMs bilaterally (excluding
IO) were obtained from the coronal T1w images by outlining
regions of interest (ROI) around the outer border of each mus-
cle, one slice behind the posterior border of the globe, using
the FSLView software (FMRIB, Oxford, UK), and the cross-
sectional area of each was recorded. All measurements were
performed by a single observer (R.D.S.P) and reviewed by a
second observer (I.D.) for quality control purposes.
Quantitative magnetic resonance analysis
A single observer (J.M.) defined additional ROIs on the TE=
8.6 ms multi-echo image of the first coronal slice posterior to
the globe, for the four rectus muscles bilaterally using the
ITK-SNAP software [10]. Only voxels wholly within the
muscle border were included to avoid partial volume errors
arising from pixels containing both muscle and orbital fat. The
small size of the superior oblique EOM prevented reliable
ROI placement and this EOM was therefore omitted from
the analysis. The mean ROI signal intensities were calculated
for each TE image and fitted to a mono-exponential decay
function to obtain the intercept, T2 decay constant and a DC
offset using the Levenberg-Marquardt algorithm implemented
in Wolfram Mathematica (Champaign, IL, USA).
Statistical methods
As the different analyses included different muscle subgroups
(all 12 muscles for ROEM analyses, ten muscles for a cross-
sectional area, eight muscles for T2 measurement) when over-
all means were calculated only the common set of muscles
were included, left and right: SR, IR, LR and MR. Mean
values in patient and control groups, reported with their re-
spective standard deviations, were compared using the two-
tailed Student’s t-test. The proportion of muscles in each
group with T1w hyperintensity was compared with Pearson’s
χ2 test. Correlations between MRI measures were analysed
using the Spearman rank correlation (rho). All statistical anal-
yses were performed using IBM SPSS Version 20.
Results
Clinical description
The demographic, clinical and quantitative MRI findings for
the patient group are summarised in Table 1, and for the con-
trol group in Table 2.
Clinical assessment of ocular movements
The overall mean ROEM was reduced by 73 % in the patient
group compared with controls (patients 13.3°, controls 49.3°,
p<0.001; Table 3), with a consistent reduction in individual
EOM ROEMs (Fig. 1A). There was no overlap between pa-
tient and control range of movement values for any muscle.
There was no significant quantitative difference in ROEM
detected between the right and left orbit in patients or controls,
or between the CPEO and KSS subgroups, when muscles
were compared both individually and collectively.
Magnetic resonance imaging analysis
On qualitative assessment, the mean atrophy score in patients
was 1.96±0.11, significantly higher than in controls (0.65±
0.59, p<0.001). Only two participants (both patients with
CPEO) had focal STIR hyperintensity within EOMs, in 2/12
and 4/12 EOMs, respectively. Focal T1w hyperintensity was
more common in patients than controls (72/108 muscles in
patients, 49/108 muscles in controls, χ2=0.002). In patients
this more commonly manifested as a streak (63 muscles) than
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a dot (nine muscles), whereas in the controls the counts were
25 and 24, respectively (Fig. 2A, 2B, 2C, 2D; Table 4).
The mean EOM cross-sectional area in patients was 43 %
lower than for controls (patient 19.2±3.9 mm2, control 33.6±
3.1 mm2, p<0.001; Fig. 2E and F; Table 3). Muscle T2s were
greater in the patient group than controls (75.6±7.0 ms, vs.
55.2±4.1 ms respectively, p<0.001; Fig. 2G, h, J; Table 3).
Consistent individual EOM cross-sectional area and T2 differ-
ences were observed (Fig. 1B and C). Quantitative differences
in mean ROEM, EOM cross-sectional area and T2 were con-
sistently significant when each muscle was assessed
individually (all p<0.01). There was no significant quantita-
tive difference in EOM cross-sectional area and T2 detected
between the right and left orbit in either patients or controls, or
between the CPEO and KSS subgroups, when muscles were
compared both individually and collectively.
Relationships between clinical and magnetic resonance
imaging measures
Correlations between clinical and MRI measures were
assessed in the patient group (Fig. 3). There was a significant
negative correlation between the patients’ overall ROEM and
the mean T2 relaxation time of the EOMs (rho=−0.89, p<
0.01). Mean EOM area did not correlate with disease duration
or ROEM. Muscles graded as showing marked atrophy had
significantly smaller relative cross sectional area (59 % of
control value) than those graded as no (98 % control value)
or mild (93 % control value) atrophy (p<0.001). However, the
difference in size between mild and no atrophy was not
significant.
Discussion
We examined MRI EOM findings in a homogenous group of
nine patients with CPEO caused by single mtDNA deletions
compared with those in age- and gender-matched healthy con-
trols. We describe differences in EOM radiological appear-
ance, cross-sectional area, and T2 in CPEO patients compared
to controls, and a significant negative correlation between
Table 1 Demographic, clinical and magnetic resonance imaging findings in patients with chronic progressive external ophthalmoplegia related to a
single mitochondrial DNA deletion
Gender Age
(years)
Clinical
diagnosis
Age of
onset (years)
Clinical characteristics Mean
ROEM
(degrees)
Mean
T2 (ms)
Mean
EOM area
(mm2)
F 19 KSS 12 PEO; ptosis; pigmentary retinopathy; proximal muscle weakness;
ataxia; SNHL; fatigue; short stature; low BMI; scoliosis
17.3 80.5 12.3
M 28 CPEO 16 PEO; ptosis; fatigue 10.6 70.1 20.5
M 28 CPEO 14 PEO; ptosis 20.9 67.8 20.4
F 28 KSS 12 PEO; ptosis; pigmentary retinopathy; fatigue; dysphagia; facial,
truncal, and proximal muscle weakness; migraine; reduced ET;
pain; cramps; migraine; SVT
8.8 85.3 12.7
F 29 KSS 6 PEO; ptosis; fatigue; learning difficulties; SNHL; pigmentary
retinopathy; DM; hypertension
25.8 69.5 15.2
F 35 CPEO 14 PEO; ptosis; fatigue; low BMI; proximal muscle weakness; pain 3.2 79.9 15.1
F 36 KSS 17 PEO; epilepsy; migraine; pigmentary retinopathy; proximal
muscle weakness
3.1 85.7 18.6
M 45 CPEO 24 PEO; ptosis; fungal keratitis (blind in RE) NA 83.2 15.4
M 52 CPEO 32 PEO; ptosis 16.6 78.0 21.7
Mean values are across left and right lateral rectus, inferior rectus, medial rectus, and superior rectus
BMI body mass index, CPEO chronic external progressive ophthalmoplegia, DM diabetes mellitus, EOM extra-ocular muscle, ET exercise tolerance,
KSS Kearns-Sayre syndrome, NA not available, RE right eye, ROEM range of eye movement, SNHL sensorineural hearing loss, SVT supraventricular
tachycardia
Table 2 Demographic, clinical and magnetic resonance imaging
findings in healthy controls
Gender Age (years) Mean ROEM
(degrees)
Mean
T2 (ms)
Mean EOM
area (mm2)
F 26 51.5 46.9 32.3
M 28 NA 53.6 36.2
F 28 50.7 56.2 34.1
M 29 45.5 48.9 36.5
F 33 44.1 57.3 29.3
F 35 53.2 57.1 34.9
F 38 49.5 58.4 28.9
F 39 50.2 58.8 32.3
M 43 49.5 58.5 37.6
Mean values are across left and right lateral rectus, inferior rectus, medial
rectus, and superior rectus
EOM extra-ocular muscle, NA not available, ROEM range of eye
movement
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EOM T2 and ROEM, suggesting MRI can provide function-
ally relevant measures of CPEO disease severity.
Earlier imaging studies have identified EOM involvement
as characteristic of CPEO [4–7, 11]. However, these are gen-
erally in smaller, patient-only case series with genetically un-
determined disease without quantitative assessment in all five
EOMs. We have, for the first time, performed a systematic
evaluation of EOM MRI signal changes in comparison with
matched controls, and correlated MRI measurements of EOM
size and condition with clinical functional measurements.
Previous reports of EOM atrophy in CPEO are mixed and
rather limited: Carlow et al. [4] examined MR, LR and IR
volume in eight clinically diagnosed CPEO patients showing
an overall 41 % reduction vs. controls. In a smaller series,
EOM atrophy was reported on CT imaging of four clinically
diagnosed CPEO patients [7]. Ortube et al. [6] detected isolat-
ed atrophy of SR and SO in five CPEO patients compared
with controls. Finally, more recent work confirmed a primary
myopathic rather than supranuclear pathway dysfunction
aetiology for the limitation of eye movement in CPEO as
evidenced by significant EOM atrophy in patients with single
or multiple mtDNA deletions compared with controls [11].
Our EOM cross-sectional area results, incorporating SR and
SO muscles in addition to MR, LR and IR, were consistent
with these findings.
EOM atrophy is reported in a number of other neuromus-
cular disorders. Cranial nerve palsies (III, IV or VI) cause
atrophy which is restricted to the muscle innervated by the
affected nerve, thereby making it straight-forward to distin-
guish the affected muscle radiologically [6]. EOM atrophy is
variably apparent in myasthenia gravis, but consistently seen
in cases left untreated [7]. Radiological atrophy of clinically
affected muscles has also been found in congenital fibrosis of
EOMs type 1 [12] and type 2 [13] (now known to be
dysinnervation syndromes). Taken together, these studies sug-
gest that EOM atrophy is a feature of late-stage muscle pa-
thology irrespective of the underlying cause, comparable to
the atrophy of skeletal limb muscles on MRI in both neuro-
genic and myopathic disorders [14].
While EOM cross-sectional area has previously been in-
vestigated in CPEO, correlations between muscle dimensions
and other quantitative MRI measures, and clinical functional
Table 3 Mean range of eye movement, extra-ocular muscle cross-sectional area and T2 relaxation time in healthy control and patient groups
Control Patient Difference
Mean s.d. n Max Min Mean s.d. n Max Min Mean (95 % CI) p-value
ROEM (degrees) 49.3 3.0 8 53.2 44.1 13.3 8.2 8 25.8 3.1 −36.0 (−42.6 to −29.3) <0.001
Area (mm2) 33.6 3.1 9 37.6 28.9 19.2 3.9 9 25.0 13.8 −14.4 (−17.9 to −10.8) <0.001
T2 (ms) 55.1 4.4 9 46.9 58.8 77.8 7.0 9 67.8 85.7 −22.7 (−28.4 to −16.9) <0.001
CI confidence interval, max maximum, min minimum, n number, ROEM range of eye movement, s.d. standard deviation
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Fig. 1 Box plot of control (blue) and patient (green) values in each extra-
ocular muscle: range of motion (A), cross-sectional area (B) and T2
relaxation time (C). The box represents 25th – 75th percentiles, the solid
line in the box represents the median value, stems are to maximum and
minimum values, o=minor outlier; +=major outlier. IO inferior oblique,
IR inferior rectus, LR lateral rectus, MR medial rectus, SO superior
oblique, SR superior rectus
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measurements, have not been reported. Such correlations, if
observed, would support the validity of MRI measures as
biologically relevant disease indices. Although we found no
correlation between muscle atrophy and reduced ROEM or
disease duration, there was a significant negative correlation
between T2 and ROEM in the patients. This indicates that
althoughmeasures relating to EOM volumemay not be useful
to quantify severity in patients with long-established disease,
measures such as EOM T2, reflecting variations in muscle
composition rather than size, may provide valid alternative
functionally relevant markers. Future studies will be required
to establish the sensitivity of EOM T2 to longitudinal change,
and to establish the sensitivity of the measure to partial vol-
ume confounds due to surrounding intra-orbital fat.
In addition to atrophic changes, we also detected EOM
MRI signal abnormalities in patients with CPEO, apparent
qualitatively as an increased frequency of T1w hyperintense
C
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Fig. 2 MRI of the orbits in the coronal plane displaying a healthy control
on the left column (panels A, C, E, G, I) and a patient with chronic
progressive external ophthalmoplegia (CPEO) on the right column
(panels B, D, F, H, J). Coronal T1-weighted (panels A and B) and corre-
sponding short-tau inversion recovery (STIR, panelsC andD) sequences
demonstrate T1-weighted hyperintense and STIR-suppressed foci intrin-
sic to the extra-ocular muscles (EOMs). If the diameter of the focus was
approximately equal in all dimensions in the coronal plane it was termed a
'dot’, whilst if unequal it was termed a 'streak’. An example of a ‘dot’ is
demonstrated in the right inferior rectus muscle on paired panels A and C,
and examples of ‘streaks’ are shown in both lateral recti on paired panels
B and D respectively (arrows). PanelsE andF demonstrate an example of
the regions of interest (ROI) used to calculate the surface area of each of
the EOMs within the right orbit in a control volunteer and CPEO patient
respectively: superior-rectus levator complex (SR); superior oblique
(SO); medial rectus (MR); lateral rectus (LR); and inferior rectus (IR).
Central ROI were placed within the same muscles for the T2-relaxometry
measurements in order to avoid contamination by the surrounding fat, as
demonstrated in panels G and H within the right orbits of a control
volunteer and CPEO patient respectively. Panels I and J demonstrate
false colour T2-relaxometry maps
Table 4 Frequency of T1-weighted magnetic resonance imaging
changes in healthy control and patient extra-ocular muscles
Controls Patients
Muscle None Dot Streak None Dot Streak
SR 16 2 0 7 0 11
IR 4 2 12 8 0 10
SO 0 14 4 4 6 8
MR 8 4 6 0 0 18
LR 13 2 3 3 2 13
IO 18 0 0 14 1 3
Total 59 24 25 36 9 63
Left and right eye combined
IO inferior oblique, IR inferior rectus, LR lateral rectus,MRmedial rectus,
SO superior oblique, SR superior rectus
Eur Radiol
streaks with very occasional STIR hyperintensity. Central
streaks of EOM hyperintensity on T1w MRI have previously
been reported in CPEO [6], although we also saw similar
appearances in some of the control EOMs. While the frequen-
cy of these hyperintensities was greater in the patient group,
their presence in the healthy control images suggests such
changes are not specific markers of CPEO pathology. Similar
changes have also been shown to occur with muscle atrophy
in patients with congenital fibrosis of the EOMs type 1 [12].
This is the first study to measure EOM T2 in a genetically
homogenous CPEO cohort. While acute inflammation pro-
longs T2, and is used to quantify EOM inflammation in
thyroid-related ophthalmopathy [15–19], inflammation is
unlikely to be a pathological substrate of EOM T2 change in
CPEO, since inflammatory infiltrates are usually absent in the
muscle biopsies of patients with mitochondrial disease. This is
supported by the predominant absence of EOM STIR
hyperintensities in our patient images, and suggests increased
intramuscular lipid as the source of T2 elevation since our T2
relaxometry acquisition was not fat-suppressed. A further anal-
ysis (results not shown) that attempted to fit a bi-exponential
model to the multi-echo decay data was not sufficient to obtain
putative lipid and muscle-water components with independent
T2 values, and more sophisticated future measurements will be
required to unambiguously establish the origin of the total mus-
cle T2 elevation. A further caveat to interpretation of the T2
findings is the potential susceptibility of the measurements to
contamination from the surrounding fatty substrate, despite our
precautions in defining conservative ROI boundaries. Never-
theless, elevated patient EOM T2 compared with controls was
consistent and, coupled with the correlation observed between
EOM T2 and ROEM measures, should motivate future more
sophisticated investigations.
Accurate, valid and reliable biomarkers of disease progres-
sion are lacking in mitochondrial disease but will be required
to assess the efficacy of novel therapies in treatment trials. We
have demonstrated the feasibility of quantitative MRI to pro-
vide measures reflecting disease severity in individual EOMs
in patients with CPEO. While EOM atrophy is a clear radio-
logical feature, its uniformity in patients and lack of correla-
tion with ROEM suggests it might not provide a meaningful
measure of progression in patients studied a significant time
after disease onset. In contrast, EOM T2 prolongation was
associated with cross-sectional variations in ROEM in our
study group, and so may represent a useful biomarker for
future clinical trials involving patients with similar disease
durations. Future investigations will evaluate the added value
of combining T2 measurement with the technically challeng-
ing but promising approach of EOM quantitative diffusion
weighted imaging [19].
In conclusion, we have examined the EOM MRI appear-
ance of patients with CPEO due to single mtDNA deletions
and demonstrated atrophy of all EOMs, more frequent T1w
hyperintensities in patients than controls and uniform prolon-
gation of EOMT2 in patients. A correlation between EOMT2
and reduced ocular excursion facility suggests that this param-
eter might provide a valid, clinically relevant, objective mea-
sure of disease severity useful to monitor patients with
established CPEO with possible value in future clinical trials.
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